253 related articles for article (PubMed ID: 11384196)
21. Nitrolinoleate inhibits platelet activation by attenuating calcium mobilization and inducing phosphorylation of vasodilator-stimulated phosphoprotein through elevation of cAMP.
Coles B; Bloodsworth A; Eiserich JP; Coffey MJ; McLoughlin RM; Giddings JC; Lewis MJ; Haslam RJ; Freeman BA; O'Donnell VB
J Biol Chem; 2002 Feb; 277(8):5832-40. PubMed ID: 11748216
[TBL] [Abstract][Full Text] [Related]
22. Natriuretic peptides induce weak VASP phosphorylation at Serine 239 in platelets.
Borgognone A; Lowe KL; Watson SP; Madhani M
Platelets; 2014; 25(1):1-7. PubMed ID: 23469931
[TBL] [Abstract][Full Text] [Related]
23. Analysis of nitric oxide-sensitive guanylyl cyclase in human platelets before and after aggregation.
Kempfert J; Behrends S
Platelets; 2003; 14(7-8):429-35. PubMed ID: 14713512
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of human platelet aggregation by S-nitrosothiols. Heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation.
Mellion BT; Ignarro LJ; Myers CB; Ohlstein EH; Ballot BA; Hyman AL; Kadowitz PJ
Mol Pharmacol; 1983 May; 23(3):653-64. PubMed ID: 6135148
[TBL] [Abstract][Full Text] [Related]
25. Role of cGMP-inhibited phosphodiesterase and sarcoplasmic calcium in mediating the increase in basal heart rate with nitric oxide donors.
Musialek P; Rigg L; Terrar DA; Paterson DJ; Casadei B
J Mol Cell Cardiol; 2000 Oct; 32(10):1831-40. PubMed ID: 11013127
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of rat platelet aggregation by the diazeniumdiolate nitric oxide donor MAHMA NONOate.
Homer KL; Wanstall JC
Br J Pharmacol; 2002 Dec; 137(7):1071-81. PubMed ID: 12429580
[TBL] [Abstract][Full Text] [Related]
27. Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase.
Chlopicki S; Olszanecki R; Marcinkiewicz E; Lomnicka M; Motterlini R
Cardiovasc Res; 2006 Jul; 71(2):393-401. PubMed ID: 16713591
[TBL] [Abstract][Full Text] [Related]
28. Protein kinase A mediates inhibition of the thrombin-induced platelet shape change by nitric oxide.
Jensen BO; Selheim F; Døskeland SO; Gear AR; Holmsen H
Blood; 2004 Nov; 104(9):2775-82. PubMed ID: 15265792
[TBL] [Abstract][Full Text] [Related]
29. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function.
Aszódi A; Pfeifer A; Ahmad M; Glauner M; Zhou XH; Ny L; Andersson KE; Kehrel B; Offermanns S; Fässler R
EMBO J; 1999 Jan; 18(1):37-48. PubMed ID: 9878048
[TBL] [Abstract][Full Text] [Related]
30. Globular adiponectin increases cGMP formation in blood platelets independently of nitric oxide.
Riba R; Patel B; Aburima A; Naseem KM
J Thromb Haemost; 2008 Dec; 6(12):2121-31. PubMed ID: 18983522
[TBL] [Abstract][Full Text] [Related]
31. Soluble guanylyl cyclase activation with HMR1766 attenuates platelet activation in diabetic rats.
Schäfer A; Flierl U; Kobsar A; Eigenthaler M; Ertl G; Bauersachs J
Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2813-8. PubMed ID: 17023677
[TBL] [Abstract][Full Text] [Related]
32. Regulation of VASP serine 157 phosphorylation in human neutrophils after stimulation by a chemoattractant.
Eckert RE; Jones SL
J Leukoc Biol; 2007 Nov; 82(5):1311-21. PubMed ID: 17684042
[TBL] [Abstract][Full Text] [Related]
33. Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling.
Mullershausen F; Friebe A; Feil R; Thompson WJ; Hofmann F; Koesling D
J Cell Biol; 2003 Mar; 160(5):719-27. PubMed ID: 12604588
[TBL] [Abstract][Full Text] [Related]
34. Phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) by the anti-platelet drug, cilostazol, in platelets.
Sudo T; Ito H; Kimura Y
Platelets; 2003 Sep; 14(6):381-90. PubMed ID: 14602552
[TBL] [Abstract][Full Text] [Related]
35. The use of oxyhaemoglobin to explore the events underlying inhibition of platelet aggregation induced by NO or NO-donors.
Salvemini D; Radziszewski W; Korbut R; Vane J
Br J Pharmacol; 1990 Dec; 101(4):991-5. PubMed ID: 1707709
[TBL] [Abstract][Full Text] [Related]
36. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
Fisch A; Michael-Hepp J; Meyer J; Darius H
Eur J Pharmacol; 1995 May; 289(3):455-61. PubMed ID: 7556414
[TBL] [Abstract][Full Text] [Related]
37. YC-1 potentiates the antiplatelet effect of hydrogen peroxide via sensitization of soluble guanylate cyclase.
Wu CC; Kuo SC; Lee FY; Teng CM
Eur J Pharmacol; 1999 Sep; 381(2-3):185-91. PubMed ID: 10554886
[TBL] [Abstract][Full Text] [Related]
38. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases.
Manns JM; Brenna KJ; Colman RW; Sheth SB
Thromb Haemost; 2002 May; 87(5):873-9. PubMed ID: 12038792
[TBL] [Abstract][Full Text] [Related]
39. The activity of constitutive nitric oxide synthase is increased by the pathway cAMP/cAMP-activated protein kinase in human platelets. New insights into the antiaggregating effects of cAMP-elevating agents.
Russo I; Doronzo G; Mattiello L; De Salve A; Trovati M; Anfossi G
Thromb Res; 2004; 114(4):265-73. PubMed ID: 15381390
[TBL] [Abstract][Full Text] [Related]
40. Regulation of VASP phosphorylation in cardiac myocytes: differential regulation by cyclic nucleotides and modulation of protein expression in diabetic and hypertrophic heart.
Sartoretto JL; Jin BY; Bauer M; Gertler FB; Liao R; Michel T
Am J Physiol Heart Circ Physiol; 2009 Nov; 297(5):H1697-710. PubMed ID: 19734360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
